Amgen and AstraZeneca announced TEZSPIRE™ (tezepelumab-ekko) is available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine.

TEZSPIRE is the first and only biologic for severe asthma that does not have a phenotype—eosinophilic or allergic—or biomarker limitation within its approved label. TEZSPIRE consistently and significantly reduced asthma attacks across Phase 2 and 3 clinical trials which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts, allergic status and fractional exhaled nitric oxide (FeNO).